I guess I would simply echo that—I thought you were asking specifically about registration as a starter—other kinds of information are critical to get out as well. There's such a course of support for transparency right now that if we limit it to clinical trial registration, which has been happening for years and years in other countries, it's really at the risk of being a pyrrhic victory. We need results reporting backed by serious enforcement measures. We need clinical study reports. It's how we make them available, making sure we protect patients privacy, and excluding material or information such as Joel described around manufacturing processes.
But information derived from patients participating in studies about the safety and effectiveness of a drug has to be made available, and that's going to be most richly available in the clinical study reports.
Lastly we need the information about how Health Canada is interpreting that evidence. We're talking about probabilities and lots of uncertainty. Regulators come to different conclusions about the same drug for the same indication. There's a lot of complexity here, and regulators can learn from each other and learn in dialogue with independent entities like the Cochrane Collaboration, which can really improve the quality of their work.
All those three things—results reporting, clinical study reports, and the decisions and the reasons for them offered by the regulator—need to come in addition to clinical trial registration.